ClinicalTrials.gov record
Completed Phase 2 Interventional

DOXIL for Consolidation Therapy in Ovarian Cancer.

ClinicalTrials.gov ID: NCT00248248

Public ClinicalTrials.gov record NCT00248248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 25, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Non-randomized Study of DOXIL Consolidation Treatment for Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneal Carcinoma.

Study identification

NCT ID
NCT00248248
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Southeastern Gynecologic Oncology
Other
Enrollment
45 participants

Conditions and interventions

Interventions

  • liposomal doxorubicin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2005
Primary completion
Sep 30, 2011
Completion
Sep 30, 2011
Last update posted
Oct 11, 2011

2005 – 2011

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Southeastern Gynecologic Oncology Atlanta Georgia 30342

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00248248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 11, 2011 · Synced Apr 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00248248 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →